Talquetamab combined with daratumumab and pomalidomide significantly prolongs progression-free survival in relapsed or refractory multiple myeloma, with 24-month estimates over 81%.
- 1 cited this week
Multiple Myeloma Research and Treatments
Moving in Cancer Discovery and New England Journal of Medicine.
- Moved, week to 23 Oct 2026
- 2
- Papers in 60 days
- 20
Add Multiple Myeloma Research and Treatments as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
The FDA has approved iberdomide for multiple myeloma based on minimal residual disease negativity, marking a first for the disease.
- In the news
Latest in Multiple Myeloma Research and Treatments
Newest first · last 60 days
TCR T cells targeting IgA- and IgG-expressing multiple myeloma eliminate HLA-A∗02:01+ MM cells in vitro and in vivo, showing promise for therapy in about 40% of European descent patients.
- Open access
- 1 cites
Navitoclax plus ruxolitinib significantly increases the proportion of patients with ≥35% spleen volume reduction at week 24 in untreated myelofibrosis, reaching 63.2% versus 31.5%.
- Open access
Daratumumab monotherapy achieves a 75% hematologic response rate and a 65% 6-month overall survival in patients with stage IIIB AL amyloidosis.
Rapid peak cilta-cel expansion is linked to increased risk of delayed neurotoxicity in patients with relapsed/refractory multiple myeloma.
Single-cell analysis reveals five distinct tumor microenvironment ecotypes in multiple myeloma, with one linked to tumor expansion and poor clinical outcomes.
Menin-MLL inhibitors increase JUND activity in MLL-rearranged leukemic cells, contributing to tumor growth and therapy resistance.
- Open access
Fibrocytes are the main collagen-producing cells in JAK2V617F-mutated myelofibrosis, accounting for nearly two-thirds of collagen production in the bone marrow.
- Open access
Degrading NSD2 with a targeted ligand degrader reverses oncogenic chromatin changes and improves survival in t(4;14) multiple myeloma models.
PKMYT1 inhibition induces DNA damage and cell death specifically in del(17p) multiple myeloma cells, offering a targeted therapeutic approach.
Epigenetic plasticity driven by genomic and cytogenetic changes enables therapy resistance and disease progression in multiple myeloma, with nearly 900 patient samples revealing key transitions.
- Open access
Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.
Elevated NF-κB activity in CD4 CAR-T cells predicts durable responses and improved survival in multiple myeloma patients treated with ide-cel.
Arlocabtagene autoleucel achieves an 87% overall response rate with durable responses in heavily pretreated relapsed/refractory multiple myeloma patients.
- Open access
Loss of DNA methylation in multiple myeloma leads to variable LINE-1 activation, with high L1 activity linked to increased proliferation and altered gene expression.
Mezigdomide reverses T-cell exhaustion by degrading IKZF1/IKZF3, restoring cytokine production and enhancing target cell killing in multiple myeloma.
- Open access
- 2 cites
Add Multiple Myeloma Research and Treatments as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3